Our privacy policy describes how Fidessa uses cookies on our website. If you continue using our website, you are consenting to our use of cookies. OK

The attraction of OTC clearing

Had an interesting week in the sunshine at the FIA annual conference at Boca Raton, Florida. Not surprisingly, the main topic was the move to bring the worlds of exchange traded and OTC derivatives together. This has been mandated by politicians/regulators on both sides of the Atlantic and will lead to the creation of a multitude of electronic platforms known as SEFs in the US and OTFs in Europe… or will it?

Despite all the noise and hoopla, market participants seem to be huddled together at the top of the diving board waiting for someone else to take the plunge first. Regulatory uncertainty is definitely one reason, but there is also a real sense that there will be far more of these things than the actual trading volume (as opposed to notional outstanding) will be able to support. Maybe a better option then is to be the guy offering the aggregation layer that allows traders to smartly scan the total liquidity across all the different platforms. By combining the available liquidity into a single virtual display, all sorts of further revenue generating opportunities start to become apparent, so maybe it’s a case of first mover disadvantage on this one.

But just as in equities, the real prize is in clearing and the ability to offer margin or position offsets between different but related instruments. The LSE’s acquisition of LCH.Clearnet looks like a great move as it will enable it to leverage the mighty OTC SwapClear franchise. On the other hand, the mountains of ETD open interest held at EUREX Clearing, CME Clearing and others provide different starting points for portfolio margining. The question then is: which will prove to be the strongest magnet?

Leave a comment

Copyright © 2019 Fidessa Group Holdings Limited. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa Group Holdings Limited.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.